Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.

Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA.

World J Gastroenterol. 2014 Jan 7;20(1):235-41. doi: 10.3748/wjg.v20.i1.235.

2.

Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.

Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS.

J Clin Gastroenterol. 2014 Mar;48(3):e22-9. doi: 10.1097/MCG.0b013e3182a54ec8.

PMID:
24045282
3.

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T.

World J Gastroenterol. 2014 Sep 21;20(35):12581-7. doi: 10.3748/wjg.v20.i35.12581.

4.

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Song do S, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM.

J Gastroenterol. 2015 Apr;50(4):445-54. doi: 10.1007/s00535-014-0978-3. Epub 2014 Jul 16.

PMID:
25027973
5.

Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.

World J Gastroenterol. 2014 Jan 21;20(3):786-94. doi: 10.3748/wjg.v20.i3.786.

6.
7.

Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.

Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H.

Hepatogastroenterology. 2014 Jun;61(132):954-7.

PMID:
26158148
8.

Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O.

Oncology. 2014;87(6):330-41. doi: 10.1159/000365993. Epub 2014 Sep 6.

PMID:
25227534
9.

Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.

He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC.

World J Gastroenterol. 2013 Jul 28;19(28):4552-8. doi: 10.3748/wjg.v19.i28.4552.

10.

Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.

Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Waki K, Tsuji K, Kohno H, Kohno H, Moriya T, Chayama K.

J Dig Dis. 2015 Sep;16(9):505-12. doi: 10.1111/1751-2980.12267.

PMID:
26121102
11.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.

PMID:
23601249
12.

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.

Song do S, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY, Yoon SK.

World J Gastroenterol. 2013 Aug 7;19(29):4679-88. doi: 10.3748/wjg.v19.i29.4679.

13.
15.

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.

Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Suzuki E, Katayama K, Imanaka K, Tamai C, Inaba Y, Sato Y, Kato M, Okusaka T.

Cancer Sci. 2014 Mar;105(3):354-8. doi: 10.1111/cas.12353. Epub 2014 Feb 18.

16.

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.

Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC.

Radiology. 2013 Nov;269(2):603-11. doi: 10.1148/radiol.13130150. Epub 2013 Jul 17.

PMID:
23864102
17.

Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.

Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y, Okusaka T.

J Gastroenterol. 2014 May;49(5):932-40. doi: 10.1007/s00535-013-0853-7. Epub 2013 Jun 23.

PMID:
23793266
18.

Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.

Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J.

World J Gastroenterol. 2014 Nov 21;20(43):16275-81. doi: 10.3748/wjg.v20.i43.16275.

19.

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S.

J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8.

20.

Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.

Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.

J Vasc Interv Radiol. 2015 Mar;26(3):320-9.e6. doi: 10.1016/j.jvir.2014.10.019. Epub 2015 Jan 19.

PMID:
25612807
Items per page

Supplemental Content

Write to the Help Desk